Vita Life SciencesASX:VLS 94 ROA % is 14.25% as of Dec. 2025, which is 13% above its 10-year median of 12.59. GuruFocus rates ASX:VLS with a GF Score™ of 94/100 and a GF Value™ of A$2.47 (Fairly Valued). The stock has 1 warning sign investors should review. Among 1,006 Drug Manufacturers companies, Vita Life Sciences ranks better than 90.26% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Vita Life Sciences's annualizedNet Income for the quarter that ended in Dec. 2025 was A$11.19 Mil.
Vita Life Sciences's average Total Assets over the quarter that ended in Dec. 2025 was A$78.50 Mil. Therefore, Vita Life Sciences's annualized ROA % for the quarter that ended in Dec. 2025 was 14.25%.
The historical rank and industry rank for Vita Life Sciences's ROA % or its related term are showing as below:
ASX:VLS'
s ROA % Range Over the Past 10 Years
Min: 7.1 Med: 12.59 Max: 19.66
Current: 13.68
During the past 13 years, Vita Life Sciences's highest ROA % was 19.66%. The lowest was 7.10%. And the median was 12.59%.
ASX:VLS's ROA % is ranked better than 90.26% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 2.685
vs ASX:VLS: 13.68
Vita Life Sciences (ASX:VLS) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Vita Life Sciences ROA % Related Terms
Vita Life Sciences ROA % Historical Data
* Premium members only.
The historical data trend for Vita Life Sciences's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vita Life Sciences's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vita Life Sciences ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vita Life Sciences's ROA % distribution charts can be found below:
* The bar in red indicates where Vita Life Sciences's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Vita Life Sciences (ASX:VLS) has a ROA % of 14.25% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Vita Life Sciences and its competitors. This is 13% above median its historical median of 12.59. Over the past decade, Vita Life Sciences' ROA % has ranged from 7.10 to 19.66. According to the industry distribution chart, Vita Life Sciences ranks #98 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 9.7%.
Is Vita Life Sciences' ROA % too high?
Vita Life Sciences' current ROA % of 14.25% is 13% above median its 10-year median of 12.59. Over the past 10 years, this metric has ranged from a low of 7.10 to a high of 19.66. The Drug Manufacturers industry median ROA % is 2.69. Vita Life Sciences' value of 14.25% is 430.7% above this industry median. Based on the distribution chart, Vita Life Sciences ranks #98 out of 1006 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Vita Life Sciences has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vita Life Sciences' ROA % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vita Life Sciences ranks #98 out of 1006 companies for ROA %. This places Vita Life Sciences in the top 10% of its industry — outperforming the majority of peers. The industry median ROA % is 2.69. Vita Life Sciences' value of 14.25% is 430.7% above this benchmark. Historically, Vita Life Sciences' own ROA % has ranged from 7.10 to 19.66 over the past decade. While the company's 10-year median is 12.59 vs. the industry median of 2.69, Vita Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.69, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vita Life Sciences's current ROA % of 14.25% is 430.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Vita Life Sciences and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vita Life Sciences's current ROA % is 14.25%, which is 13% above median its own 10-year median of 12.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vita Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Vita Life Sciences (ASX:VLS) is currently considered Fairly Valued. The stock's GF Value™ is A$2.47, compared to a current price of A$2.50 — trading 1.2% above its estimated fair value. The current ROA % is 14.25%, which is 13% above median its 10-year median of 12.59 and 430.7% above the Drug Manufacturers industry median of 2.69. Vita Life Sciences' overall GF Score™ is 94/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Vita Life Sciences (ASX:VLS), the current ROA % is 14.25% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vita Life Sciences (ASX:VLS) Overvalued in 2026?
Based on GuruFocus' analysis, Vita Life Sciences stock appears to be overvalued.
The current stock price of A$2.50 is trading 1.2% above its estimated GF Value™ of A$2.47.
GuruFocus considers Vita Life Sciences to be Fairly Valued.
Key valuation signals for ASX:VLS:
ROA %: 14.25% (13% above median its 10-year median of 12.59)
GF Value™: A$2.47 vs. price of A$2.50 (1.2% above fair value)
Industry Position: 430.7% above the Drug Manufacturers median (#98 of 1006)
No single metric tells the full story. See the ASX:VLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vita Life Sciences Ltd is an Australian-based pharmaceutical and healthcare company involved in formulating, packaging, selling, and distributing vitamins and supplements. It produces a wide range of premium supplements, vitamins, minerals, herbs, and superfoods catered to all age categories and health conditions. The company markets its products through pharmacies and health food stores under the VitaHealth, VitaScience, and Herbs of Gold brands throughout the Asia-Pacific region. Vita Life Sciences has two operating segments: VMS Operational, which generates maximum revenue, and VMS Investments. Geographically, the Group generates maximum revenue from Malaysia and Singapore, and the rest from Australia, and China and Vietnam.
94GF Score
Get the complete analysis for ASX:VLS
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VLS has been successfully added to your 
